Market: NASD |
Currency: USD
Address: Friedrich-Miescher-Strasse 15
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Show more
📈 CureVac N.V. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$6.25
-
Upside/Downside from Analyst Target:
14.82%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
100-200%
-
Net Income Growth Range (1Y):
100-200%
-
Revenue Growth Range (1Y):
>500%
-
Upcoming Earnings Date:
2025-11-12
-
EPS Estimate:
0.10
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for CureVac N.V.
| Date | Reported EPS |
|---|
| 2025-11-11 (estimated upcoming) | - |
| 2025-08-15 | -0.26 |
| 2025-05-20 | -0.23 |
| 2025-04-11 | -0.14 |
| 2024-11-12 | 1.5 |
| 2024-08-15 | -0.32 |
| 2024-05-23 | -0.31 |
| 2024-04-25 | -0.39 |
| 2023-11-14 | -0.22 |
| 2023-08-17 | -0.3 |
| 2023-05-30 | -0.27 |
| 2023-04-25 | -0.68 |
| 2022-11-16 | -0.25 |
| 2022-08-18 | -0.31 |
| 2022-05-25 | -0.08 |
| 2022-04-28 | -1.97 |
| 2022-01-02 | -0.03 |
| 2021-08-16 | -0.61 |
| 2021-05-26 | -0.44 |
| 2021-04-27 | -0.32 |
| 2020-11-30 | -0.24 |
📰 Related News & Research
No related articles found for "curevac nv".
